基于咳喘药学服务门诊的慢性阻塞性肺疾病患者吸入制剂使用效果分析  

Efficacy of Inhaled Formulations in Patients with Chronic Obstructive Pulmonary Disease Based on Cough and Wheeze Pharmaceutical Care Clinic

作　　者：于小杰[1] 赵艳敏 杨文明[1] 王娜[1] YU Xiaojie;ZHAO Yanmin;YANG Wenming;WANG Na(The First Hospital of Qinhuangdao,Qinhuangdao,Hebei,China 066000)

机构地区：[1]河北省秦皇岛市第一医院,河北秦皇岛066000

出　　处：《中国药业》2024年第18期22-26,共5页China Pharmaceuticals

基　　金：河北省秦皇岛市科学技术研究与发展计划项目[201902A210]。

摘　　要：目的探讨基于咳喘药学服务门诊(CWPC)的慢性阻塞性肺疾病(COPD)患者使用吸入制剂的效果。方法收集医院CWPC2021年10月至2023年6月收治的130例COPD患者的基本信息,采用自身对照法,比较接受CWPC干预前(初诊)、干预后(持续干预1年)的临床结局[包括吸入装置正确操作率、用药依从性评分、改良版英国医学研究委员会呼吸困难问卷(mMRC)评分、COPD患者自我评估测试(CAT)评分、1年内急性加重次数、不良反应发生率]和人文结局[欧洲五维五水平健康(EQ-5D-5L)量表评分、患者满意度]。结果干预后,患者的吸入装置正确操作率由36.11%升至83.33%、用药依从性评分由4.50分升至6.50分,mMRC评分由2.00分降至1.00分,CAT评分由21.00分降至12.00分,不良反应发生率由29.23%降至16.92%,1年内急性加重次数由2.00次降至1.00次,EQ-5D-5L量表评分由62.00分升至70.00分,患者满意度得分由6.00分升至12.00分,干预前后各数据差异均有统计学意义(P<0.05)。结论临床药师通过CWPC可显著提高吸入制剂治疗COPD的效果。Objective To investigate the efficacy of inhaled formulations in patients with chronic obstructive pulmonary disease(COPD)based on the cough and wheeze pharmaceutical care clinic(CWPC).Methods The basic information of 130 patients with COPD admitted to the CWPC of a hospital from October 2021 to June 2023 was collected,and the self-control method was used to compare the clinical outcomes[correct operation rate of inhalation devices,medication adherence score,modified British Medical Research Council(mMRC)score,COPD Assessment Test(CAT)score,frequency of acute exacerbations within one year,incidence of adverse reactions]and the humanistic outcomes[European Quality of Life-Five Dimension-Five Level(EQ-5D-5L)Scale score,patients'satisfaction level]before the intervention(initial diagnosis)and after intervention(continuous intervention for one year)of CWPC.Results After the intervention,the patients'correct operation rate of the inhalation devices increased from 36.11%to 83.33%,the medication adherence score increased from 4.50 points to 6.50 points,the mMRC score decreased from 2.00 points to 1.00 point,the CAT score decreased from 21.00 points to 12.00 points,the incidence of adverse reactions decreased from 29.23%to 16.92%,the frequency of acute exacerbations within one year decreased from 2.00 times to 1.00 time,the EQ-5D-5L Scale score increased from 62.00 points to 70.00 points,the patients'satisfaction level increased from 6.00 points to 12.00 points,and the above indexes were significantly different from those before intervention(P<0.05).Conclusion Clinical pharmacists can significantly improve the efficacy of inhaled formulations for COPD through the CWPC.

关 键 词：咳喘药学服务门诊 药学服务 慢性阻塞性肺疾病 吸入制剂 临床结局 人文结局 

分 类 号：R95[医药卫生—药学]